Clinical Trials Update

NEOK002 (previously known as ABL209) is a novel, bispecific ADC designed to simultaneously target two key cancer antigens—Epidermal Growth Factor Receptor (EGFR), a key oncogenic driver in multiple tumor types, and Mucin-1 (MUC1), a tumor-associated antigen characterized by aberrant glycosylation and overexpression.

Pfizer has discontinued development of its early-stage immune-stimulating antibody conjugate (ISAC) PF-08046037, an investigational therapy targeting PD-L1, as part of a strategic realignment of its oncology pipeline. The decision, described as being for 'strategic business reasons' and not due to safety or efficacy concerns, comes after a series of notable clinical successes and high-profile deals that have reshaped Pfizer’s approach to cancer drug development.

Rakuten Medical is Developing ASP-1929 photoimmunotherapy Based on the Alluminox® Platform as a Selective Cancer Treatment with Focused Local Control

Recent advances in antibody-drug conjugate (ADC) technology have enabled the development of highly potent, tumor-targeted therapeutics with improved efficacy and safety. Sutro Biopharma, leveraging its site-specific and cell-free protein synthesis platform, has reported robust preclinical data for its pipeline of next-generation ADCs at the annual meeting of the American Association for Cancer Research (AACR), held April 17 - 22, 2026.

Recent Advances in the Clinical Development of First- and Best-in-Class Antibody-Drug Conjugates: Pipeline Update from Adcendo

A promising avenue is the targeting of CD37, a tetraspanin family member broadly expressed on malignant myeloid blasts but with limited expression on normal hematopoietic stem cells. Debio 1562M,** a second-generation novel antibody-drug conjugate (ADC) developed by Debiopharm, is designed to target CD37 and deliver a potent cytotoxic payload directly to tumor cells. Here, we review the preclinical development, mechanism of action, and therapeutic potential of Debio 1562M in AML and MDS.

ZW191: A Next-Generation FRα-Targeted ADC Demonstrates Promising Efficacy and Safety in Advanced Solid Tumors

At the annual meeting of the American Association for Cancer Research (AACR), held April 17 - 22, 2026, in San Diego, CA., new preclinical data will be presented for three proprietary antibody-drug conjugate (ADC) assets—CS5007 (EGFR/HER3 ADC), CS5006 (ITGB4 ADC), and CS5008 (DLL3/SSTR2 ADC)—being developed by CStone Pharmaceuticals.

Patients treated with QLS5132, a novel antibody-drug conjugate (ADC) developed by Qilu Pharmaceutical Co. experienced clinical benefit. This conclusion is based on results from a phase 1 clinical study presented at the annual meeting of the American Association for Cancer Research, held April 17 - 22. 2026, in San Diego Ca.

Data from a Phase 1/2 dose-escalation and expansion study of JK06, a 5T4-targeted antibody-drug conjugate (ADC) being developed by SalubrisBio, have shown promising results...